Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic Escherichia coli as a prophylactic against diarrhea

References

• Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA, et al. Characterization of mucosal immune responses to Enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol. 2016;23(1):55–11. doi:10.1128/CVI.00617-15.
   PubMedGoogle Scholar
• DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH, Kalas JP. Pathogenesis of Escherichia coli diarrhea. N Engl J Med. 1971;285(1):1–9. doi:10.1056/NEJM197107012850101.
   PubMed Web of Science ®Google Scholar
• Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol. 1996;4(11):444–452. doi:10.1016/0966-842X(96)10068-8.
   PubMed Web of Science ®Google Scholar
• Qadri F, Das SK, Faruque AS, Fuchs GJ, Albert MJ, Sack RB, Svennerholm AM. Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol. 2000;38:27–31.
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis. 1988;158(2):372–377. doi:10.1093/infdis/158.2.372.
   PubMed Web of Science ®Google Scholar
• Cravioto A, Reyes RE, Ortega R, Fernández G, Hernández R, López D. Prospective study of diarrhoeal disease in a cohort of rural Mexican children: incidence and isolated pathogens during the first two years of life. Epidemiol Infect. 1988;101(1):123–134. doi:10.1017/S0950268800029289.
   PubMed Web of Science ®Google Scholar
• Levine MM, Nalin, DR, Hoover, DL, Bergquist, EJ, Hornick, RB and Young, CR. Immunity to enterotoxigenic Escherichia coli. Infect Immun. 1979;23(3):729–736. doi:10.1128/IAI.23.3.729-736.1979.
   PubMed Web of Science ®Google Scholar
• Lopez-Vidal Y, Calva JJ, Trujillo A, de Leon AP, Ramos A, Svennerholm A-M, Ruiz-Palacios GM. Enterotoxins and adhesins of enterotoxigenic Escherichia coli: are they risk factors for acute diarrhea in the community? J Infect Dis. 1990;162(2):442–447. doi:10.1093/infdis/162.2.442.
   PubMed Web of Science ®Google Scholar
• Freedman DJ, Tacket C, Delehanty A, Maneval D, Nataro J, Crabb J. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis. 1998;177(3):662–667. doi:10.1086/jid.1998.177.issue-3.
   PubMed Web of Science ®Google Scholar
• Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol. 2011;46(7–8):862–868. doi:10.3109/00365521.2011.574726.
   PubMed Web of Science ®Google Scholar
• Savarino SJ, McKenzie R, Tribble DR, Porter CK, O’Dowd A, Cantrell JA, Sincock SA, Poole ST, DeNearing B, Woods CM, et al. Prophylactic efficacy of hyperimmune bovine colostral antiadhesin antibodies against Enterotoxigenic Escherichia coli diarrhea: a randomized, double-blind, placebo-controlled, phase 1 trial. J Infect Dis. 2017;216(1):7–13. doi:10.1093/infdis/jix144.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Link H, Hoang Y, Guesry P, Hilpert H, Levine MM. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med. 1988;318(19):1240–1243. doi:10.1056/NEJM198805123181904.
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Lowe B, Verenkar M, Ashley D, Steffen R, Tornieporth N, von Sonnenburg F, Waiyaki P, DuPont H. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis. 2002;185(4):497–502. doi:10.1086/jid.2002.185.issue-4.
   PubMed Web of Science ®Google Scholar
• Porter CK, Riddle MS, Tribble DR, Putnam SD, Rockabrand DM, Frenck RW, Rozmajzl P, Kilbane E, Fox A, Ruck R, et al. The epidemiology of travelers’ diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. Diagn Microbiol Infect Dis. 2010;66(3):241–247. doi:10.1016/j.diagmicrobio.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Alam MM, Aktar A, Afrin S, Rahman MA, Aktar S, Uddin T, Rahman MA, Mahbuba DA, Chowdhury F, Khan AI, et al. Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults. PLoS Negl Trop Dis. 2014;8(4):e2822. doi:10.1371/journal.pntd.0002822.
   PubMed Web of Science ®Google Scholar
• Qadri F, Saha, A, Ahmed, T, Al Tarique, A, Begum, YA and Svennerholm, AM. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Infect Immun. 2007;75(8):3961–3968. doi:10.1128/IAI.00459-07.
   PubMed Web of Science ®Google Scholar
• Rao MR, Wierzba, TF, Savarino, SJ, Abu-Elyazeed, R, El-Ghoreb, N, Hall, ER, Naficy, A, Abdel-Messih, I, Frenck Jr, RW, Svennerholm, AM and Clemens, JD, et al. Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea. J Infect Dis. 2005;191(4):562–570. doi:10.1086/427662.
   PubMed Web of Science ®Google Scholar
• Savarino SJ, McKenzie R, Tribble DR, Porter CK, O’Dowd A, Sincock SA, Poole ST, DeNearing B, Woods CM, Kim H, et al. Hyperimmune bovine colostral anti-CS17 antibodies protect against Enterotoxigenic Escherichia coli diarrhea in a randomized, doubled-blind, placebo-controlled human infection model. J Infect Dis. 2019;220(3):505–513. doi:10.1093/infdis/jiz135.
   PubMed Web of Science ®Google Scholar
• Savarino SJ, McKenzie R, Tribble DR, Porter CK, O’Dowd A, Cantrell JA, Sincock SA, Poole ST, DeNearing B, Woods CM, et al. Prophylactic efficacy of hyperimmune bovine colostral antiadhesin antibodies against Enterotoxigenic Escherichia coli diarrhea: a randomized, double-blind, placebo-controlled, phase 1 trial. J Infect Dis. 2017;216(1):7–13. doi:10.1093/infdis/jix144.
   PubMed Web of Science ®Google Scholar
• Savarino SJ, McKenzie, R, Tribble, DR, Porter, CK, O’Dowd, A, Sincock, SA, Poole, ST, DeNearing, B, Woods, CM, Kim, H and Grahek, SL, et al. Hyperimmune bovine colostral anti-CS17 antibodies protect against enterotoxigenic Escherichia coli diarrhea in a randomized, doubled-blind, placebo-controlled human infection model. J Infect Dis. 2019;21(5418505):505–513.
   Google Scholar
• Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm A-M, Bourgeois AL, Walker RI, et al. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol. 2011;18(10):1719–1727. doi:10.1128/CVI.05194-11.
   PubMedGoogle Scholar
• Porter CK, Riddle MS, Alcala AN, Sack DA, Harro C, Chakraborty S, Gutierrez RL, Savarino SJ, Darsley M, McKenzie R, et al. An evidenced-based scale of disease severity following human challenge with Enteroxigenic Escherichia coli. PLoS One. 2016;11(3):e0149358. doi:10.1371/journal.pone.0149358.
   PubMed Web of Science ®Google Scholar
• Lapa JA, Sincock SA, Ananthakrishnan M, Porter CK, Cassels FJ, Brinkley C, Hall ER, van Hamont J, Gramling JD, Carpenter CM, et al. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol. 2008;15(8):1222–1228. doi:10.1128/CVI.00491-07.
   PubMedGoogle Scholar
• Halvorsen T, VALVATNE H, GREWAL HMS, GAASTRA W, SOMMERFELT H. Expression of colonization factor antigen I fimbriae by enterotoxigenic Escherichia coli; influence of growth conditions and a recombinant positive regulatory gene. APMIS. 1997;105(3):247–254. doi:10.1111/apm.1997.105.issue-1-6.
   PubMed Web of Science ®Google Scholar
• Tobias J, Svennerholm A-M, Carlin NIA, Lebens M, Holmgren J. Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. Vaccine. 2011;29(48):8863–8869. doi:10.1016/j.vaccine.2011.09.096.
   PubMed Web of Science ®Google Scholar
• Coster TS, Wolf MK, Hall ER, Cassels FJ, Taylor DN, Liu CT, Trespalacios FC, DeLorimier A, Angleberger DR, McQueen CE, et al. Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infect Immun. 2007;75(1):252–259. doi:10.1128/IAI.01131-06.
   PubMed Web of Science ®Google Scholar
• Olson S, Hall, A, Riddle, MS and Porter, CK. Travelers’ diarrhea: update on the incidence, etiology and risk in military and similar populations - 1990-2005 versus 2005-2015, does a decade make a difference? Trop Dis Travel Med Vaccines. 2019;5:1. doi:10.1186/s40794-018-0077-1.
   PubMedGoogle Scholar
• Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers’ diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009;80(4):609–614. doi:10.4269/ajtmh.2009.80.609.
   PubMed Web of Science ®Google Scholar
• Kharat VB, Ahmed M, Jiang Z-D, Riddle MS, DuPont HL. Colonization factors in Enterotoxigenic Escherichia coli strains in travelers to Mexico, Guatemala, and India compared with children in Houston, Texas. Am J Trop Med Hyg. 2017;96(1):83–87. doi:10.4269/ajtmh.16-0405.
   PubMed Web of Science ®Google Scholar
• Vidal RM, Muhsen K, Tennant SM, Svennerholm A-M, Sow SO, Sur D, Zaidi AKM, Faruque ASG, Saha D, Adegbola R, et al. Colonization factors among enterotoxigenic Escherichia coli isolates from children with moderate-to-severe diarrhea and from matched controls in the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis. 2019;13(1):e0007037. doi:10.1371/journal.pntd.0007037.
   PubMed Web of Science ®Google Scholar
• Isidean SD, Riddle MS, Savarino SJ, Porter CK. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine. 2011;29(37):6167–6178. doi:10.1016/j.vaccine.2011.06.084.
   PubMed Web of Science ®Google Scholar
• Poole S, Maciel Jr M, Ramakrishnan A, Liu Y, Dori K, Prouty MG, et al. Development, characterization, and immunological evaluation of parenterally delivered CS6-subunit vaccine candidates against enterotoxigenic E. coli (ETEC). in E. coli and the mucosal immune system. Ghent (Belgium); 2019.
   Google Scholar
• Thomas LV, Cravioto A, Scotland SM, Rowe B. New fimbrial antigenic type (E8775) that may represent a colonization factor in enterotoxigenic Escherichia coli in humans. Infect Immun. 1982;35(3):1119–1124. doi:10.1128/IAI.35.3.1119-1124.1982.
   PubMed Web of Science ®Google Scholar
• Sabui S, Ghosal A, Dutta S, Ghosh A, Ramamurthy T, Nataro JP, Hamabata T, Chatterjee NS. Allelic variation in colonization factor CS6 of enterotoxigenic Escherichia coli isolated from patients with acute diarrhoea and controls. J Med Microbiol. 2010;59(Pt 7):770–779. doi:10.1099/jmm.0.017582-0.
   PubMed Web of Science ®Google Scholar
• Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopoulos N, Blackwelder WC, Barry EM, Pasetti MF. Bioactive immune components of anti-diarrheagenic Enterotoxigenic Escherichia coli hyperimmune bovine colostrum products. Clin Vaccine Immunol. 2017;24(8). doi:10.1128/CVI.00186-16.
   PubMedGoogle Scholar
• Chakraborty S, Randall A, Vickers TJ, Molina D, Harro CD, DeNearing B, Brubaker J, Sack DA, Bourgeois AL, Felgner PL, et al. Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection. NPJ Vaccines. 2019;4:37. doi:10.1038/s41541-019-0131-7.
   PubMed Web of Science ®Google Scholar